1. Home
  2. GSIW vs MRKR Comparison

GSIW vs MRKR Comparison

Compare GSIW & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSIW

Garden Stage Limited

N/A

Current Price

$30.02

Market Cap

33.5M

Sector

N/A

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.47

Market Cap

27.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSIW
MRKR
Founded
2016
1999
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.5M
27.7M
IPO Year
2022
2010

Fundamental Metrics

Financial Performance
Metric
GSIW
MRKR
Price
$30.02
$1.47
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
2.2K
121.0K
Earning Date
08-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.61
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.81
52 Week High
$36.90
$4.07

Technical Indicators

Market Signals
Indicator
GSIW
MRKR
Relative Strength Index (RSI) 65.93 47.81
Support Level $0.11 $1.34
Resistance Level $32.25 $1.55
Average True Range (ATR) 0.79 0.09
MACD -0.62 -0.01
Stochastic Oscillator 31.93 35.06

Price Performance

Historical Comparison
GSIW
MRKR

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.

Share on Social Networks: